| ¨ ISCHEMIC HEART
DISEASE 
u Stenting
provides maximal reduction in repeat target vessel
revascularization (TVR) with more than 40%
suppression.
Abciximab (Abx) and stent have a similar efficacy in
diabetics.
In the EPISTENT trial,
patients undergoing coronary interventions were
randomized to one of the three arms:
1) Stent + Abx
2) PTCA +
Abx
3) Stent +
Placebo
After six months
follow-up:
6 months
|
Stent / Abx
(n =
809)
|
Stent / Placebo
(n =
809)
|
PTCA / Abx
(n =
809)
|
Reduction
by Abx
by Stent
|
| TVR all patients |
8.7%
|
10.6%
|
15.4%
|
18%
|
43.5%
|
| TVR in diabetics |
8.1%
|
16.6%
|
18.4%
|
51.2%
|
55.9%
|
[Cura F.A. et al. JACC
1999; 33: 11A]
 Home page ACC Congress '99
Home page EINTHOVEN.net
|